Clinical application of genotypic co-receptor tropism testing from viral RNA and proviral DNA: week 24 analysis of the Berlin maraviroc cohort

Objectives: Before initiating an antiretroviral combination therapy which includes Maraviroc as one of its components, a coreceptor tropism test has to be performed. As Maraviroc is only effective against HIV strains that are using CCR5 as coreceptor a thoroughly validated and reliable assay should be performed. In case of treatment change due to toxicity, testing should also be possible using proviral DNA. Supplement: Abstracts of the Tenth International Congress on Drug Therapy in HIV Infection http://www.biomedcentral.com/content/pdf/1758-2652-13-S4-info.pdf Conference: Tenth International Congress on Drug Therapy in HIV Infection 7-11 November 2010 Glasgow, UK (Published: 8 November 2010) doi:10.1186/1758-2652-13-S4-P129 Cite this article as: Obermeier et al.: Clinical application of genotypic coreceptor tropism testing from viral RNA and proviral DNA: week 24 analysis of the Berlin maraviroc cohort. Journal of the International AIDS Society 2010 13(Suppl 4):P129. Full text: PubMed Central:  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112904/